Skip to main content
APMDApnimed, Inc.Hold4.8·$26.69
APMD · Why this verdict

Why Apnimed (APMD) is rated HOLD

Updated

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

VerdictHOLD
Overall score4.8/10
ConfidenceMEDIUM
MacroRISK_OFF
TrendMatrix Research · core thesis

Engine thesis — one sentence

Apnimed screens with strong financial-strength characteristics and net insider buying, and ranks as a growth leader among industry peers, with a value profile that skews constructive on price-to-earnings. No current share price is available this run, so no trade setup or risk/reward can be computed.

Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.

Thesis pillars

The company screens with strong financial strength, flagged explicitly via a high Piotroski F-Score reading in the quality assessment.

Deteriorating
Quality breakdown
Expectation
The financial-strength signal should hold or improve, with the Piotroski-style read staying at the strong end of its scale.

CounterA single financial-strength score can mask the fact that broader quality inputs, such as margin and growth notes, are largely absent from this assessment, so the strong read may not capture the full risk picture.

Recent insider activity is net bullish, with two buy transactions and no sales, adding roughly 325,000 shares on a net basis.

Stable
Insider transaction read
Expectation
Insider buying should continue, or at least not reverse into net selling, over the following quarters.

CounterThe insider read carries low confidence in the underlying assessment, and a single reporting period of buying is a thin sample from which to infer sustained insider conviction.

The company ranks as an industry growth leader relative to peers, with the growth-rank component sitting at the top of its scale.

Deteriorating
Peer-rank breakdown
Expectation
The company should maintain or extend its relative growth leadership position versus industry peers.

CounterPeer-relative growth rank says nothing about absolute growth durability or path to profitability, and the growth dimension itself lacks supporting notes or data in this bundle, limiting confidence in the read.

Valuation components are mixed but skew constructive, with the price-to-earnings read the strongest of the three inputs, EV/EBITDA moderately above average, and price-to-sales the softest of the group.

Deteriorating
Components
Expectation
The price-to-sales component should improve from its current soft reading as the overall value picture firms up.

CounterThe value assessment's confidence is only moderate, and without any accompanying notes to explain the scoring, the valuation read here is less reliable than for names with fuller data coverage.

Per-dimension breakdown

Value

7.2/10data confidence 67%
ComponentSub-score
P/E10.0
P/S3.8
EV/EBITDA0.0
Analyst target9.0
  • Attractively valued

Quality

5.2/10data confidence 71%
ComponentSub-score
Gross margin10.0
Op margin0.0
Current ratio7.8
Moat4.8
Piotroski F3.3
  • No competitive moat
  • Weak Piotroski F-Score: 3/9

Growth

0.0/10data confidence 33%
ComponentSub-score
Rev growth0.0
  • Declining revenue: -29%

Momentum

2.0/10data confidence 100%
ComponentSub-score
RSI4.5
MACD0.3
OBV1.0
MA position3.5
Volume0.7
  • Volume distribution (falling OBV)

Sentiment

7.2/10data confidence 100%
ComponentSub-score
LLM sentiment7.0
Analyst rating5.0
Price target10.0
  • LLM news sentiment: +0.40 (n=1)
  • Analyst upside: 92%

Insider

8.0/10data confidence 50%
ComponentSub-score
materiality8.0
insider conviction8.0
  • Notable insider buying — $5,200,000 (0.476% of mkt cap)

Peer rank

5.0/10data confidence 80%
ComponentSub-score
value rank6.7
quality rank10.0
growth rank2.6
  • Attractive P/E vs peers
  • Best-in-class margins

Technical

6.7/10data confidence 100%
ComponentSub-score
bollinger7.9
support resistance8.9
52w position4.9
gap5.0

Risk (lower is worse)

4.9/10data confidence 60%
ComponentSub-score
days to cover9.9
volatility0.0
debt equity4.7

Catalyst

2.5/10data confidence 100%
ComponentSub-score
earnings history0.0
earnings timing5.0
surprise avg0.0
news activity5.0

How the verdict was assembled

Engine trigger

Multiple concerning factors. Consider reducing position. | News modifier +1 (SELL_IF_HOLDING → HOLD_IF_HOLDING).

Engine technical detail
verdict_path: L4:PATH_F_SELL|L3:NEWS_MOD=+1
Passed (7)
  • ASYMMETRY:4.2>=1.5
  • INSIDER:OK
  • 8K:CLEAN
  • NEWS_EVENTS:NONE_RECENT
  • EARNINGS_PROXIMITY:59d clear
  • SEMI_CYCLE_PEAK:CLEAR
  • MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
  • MOMENTUM:2.0<4.5
Warning (0)

none

Reward-to-Risk
4.21
Upside
+63.1%
Downside
15.0%
Sizing output
AVOID

Setup No clear chart pattern; technical signals are mixed

EdgeInst Constrain Small cap ($1.1B) below institutional reach

SuitabilitySpeculative Binary industry: Biotechnology

Investment implication

The F-path SELL output reflects an overall score of 4.3 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. The strongest dimension ( Insider at 8.0) was not enough to lift the adjusted overall above the threshold. Co-occurring failed gates ( MOMENTUM:2.0<4.5) reinforce the read. Current asymmetry R:R is 4.21 — supplementary context, not the trigger for this path.

The strongest dimensions are Insider at 8.0, Value at 7.2, and Sentiment at 7.2; the weakest are Growth at 0.0, Momentum at 2.0, and Catalyst at 2.5. The V9 engine flagged 1 failed gate, producing an asymmetric reward-to-risk of 4.21 and an engine sizing output of AVOID.

What would invalidate the thesis

Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.

  • P1Strong Piotroski Financial Strength

    Trip ifThe Piotroski F-Score reading drops to 4 out of 9 or below, down from the current 7 out of 9.

  • P2Net Bullish Insider Buying

    Trip ifNet insider selling exceeds 100,000 shares in a future reporting period, reversing the current net buying of roughly 325,000 shares.

  • P3Industry Growth Leadership Rank

    Trip ifThe growth-rank component falls below 5.0 on its 0-10 peer-relative scale, down from the current top-of-scale reading of 10.0.

  • P4Constructive Pe Led Valuation

    Trip ifThe price-to-earnings component score falls below 5.0 on its 0-10 scale, down from the current strong 9.4 reading.

Engine reasoning is mechanically derived from pipeline gate outputs. See decision view.

Home Stocks APMD Why this verdict